NeuroSense Therapeutics Warrant
NRSNW
2 hedge funds and large institutions have $41.3K invested in NeuroSense Therapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
156% more capital invested
Capital invested by funds: $16.1K → $41.3K (+$25.2K)
0.12% less ownership
Funds ownership: 0.4% → 0.28% (-0.12%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.05K |
| 2 |
CS
Clear Street
New York
|
-$809 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$535 |
NRSNW Hedge Fund Activity: Q2 2025 in Review
2 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2025, worth a combined $41.3K — up 156% from $16.1K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRSNW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Warberg Asset Management, exiting entirely with an estimated $2.05K sold.
- 2 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2025, down from 3 in Q1 2025.
- Funds reported $41.3K of NeuroSense Therapeutics Warrant stock for Q2 2025, up 156% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest NeuroSense Therapeutics Warrant seller in Q2 2025 was Warberg Asset Management, an estimated $2.05K sold.
Based on aggregated 13F filings for Q2 2025.